Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | MPL | P40238 | 2/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607667 | 1.00 | PDE2A (0.46) | PDE2AIDO1MPLTAS2R14PTPN5 | |
| SCHEMBL27858715 | 0.83 | KDM1A (0.39) | PDE2AKDM1AKCNH2KDM1B | |
| SCHEMBL16046268 | 0.82 | KDM1A (0.36) | PDE2AIDO1KDM1AKCNH2KDM1B | |
| SCHEMBL5350038 | 0.82 | KDM1A (0.36) | PDE2AIDO1KDM1AKCNH2KDM1B | |
| SCHEMBL29762963 | 0.81 | IDO1 (0.44) | PDE2AIDO1MPLTAS2R14PTPN5 | |
| SCHEMBL283936 | 0.81 | IDO1 (0.44) | PDE2AIDO1MPLTAS2R14PTPN5 | |
| SCHEMBL31082039 | 0.80 | PDE2A (0.41) | PDE2AIDO1MPLPTPN5KDM1A | |
| SCHEMBL7863398 | 0.80 | PTPN5 (0.41) | TAS2R14PTPN5MAPTXBP1NPSR1 | |
| SCHEMBL29637726 | 0.80 | PTPN5 (0.41) | TAS2R14PTPN5MAPTXBP1NPSR1 | |
| SCHEMBL1104683 | 0.79 | ALDH1A1 (0.41) | KDM1AKCNH2KDM1BMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120051465-A | Novel heterobicyclic compounds for inhibiting YAP-TEAD interactions and pharmaceutical compositions containing the same | 韩美药品株式会社 | 2025-05-27 | — | — | CN | disclosed |
| WO-2025096589-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| CN-119301113-A | Novel heterocyclic carbonyl cyclic compounds as MAGL inhibitors | 豪夫迈·罗氏有限公司 | 2025-01-10 | — | — | CN | disclosed |
| EP-4476224-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2024-12-18 | — | — | EP | disclosed |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| WO-2024220917-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| EP-4448513-A1 | 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF | BeiGene Switzerland GmbH (CH) | 2024-10-23 | — | — | EP | disclosed |
| WO-2024201248-A1 | COMPOUNDS AND METHODS FOR DEGRADING GSPT1 | PIN THERAPEUTICS, INC. (KR) | 2024-10-03 | — | — | WO | disclosed |
| CN-118679163-A | Bicyclic heteroaryl compounds and uses thereof | 上海奕拓医药科技有限责任公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-111263785-B | Lewis acid polymerization catalyst | 陶氏环球技术有限责任公司 | 2023-06-09 | — | — | CN | disclosed |
| CN-111263784-B | Method for producing polyols | 陶氏环球技术有限责任公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-112409223-B | Amide compound and medical application thereof as STING inhibitor | 中国药科大学 | 2023-01-31 | — | — | CN | disclosed |
| CN-115335369-A | GEM-disubstituted piperidine melanocortin subtype-2 receptor (MC 2R) antagonists and uses thereof | 克林提克斯医药股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
| WO-2022232632-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| WO-2022138791-A1 | EP2 ANTAGONIST | 小野薬品工業株式会社 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022109268-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | CYTOKINETICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | PDE2A 212/4885IDO1 4536/4885MPL 4828/4885 |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | MAGI3, MAG, MAGT1 | PDE2A 1601/4885IDO1 1419/4885MPL 462/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | PDE2A 1875/4885IDO1 805/4885MPL 2660/4885 |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | PDE2A 212/4885IDO1 4536/4885MPL 4828/4885 |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | PDE2A 212/4885IDO1 4536/4885MPL 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.